Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK)
0874.HK Stock Price Chart
Explore Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited interactive price chart. Choose custom timeframes to analyze 0874.HK price movements and trends.
0874.HK Company Profile
Discover essential business fundamentals and corporate details for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
30 Oct 1997
Employees
28.14K
Website
https://www.gybys.com.cnCEO
Hong Li
Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
0874.HK Financial Timeline
Browse a chronological timeline of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 13 Mar 2026
Upcoming earnings on 25 Oct 2025
Dividend declared on 29 Aug 2025
A dividend of $0.44 per share was announced, adjusted to $0.44. The dividend will be paid on 26 Sept 2025.
Earnings released on 15 Aug 2025
EPS came in at $0.47 falling short of the estimated $0.49 by -5.19%, while revenue for the quarter reached $21.18B .
Dividend declared on 16 Jun 2025
A dividend of $0.44 per share was announced, adjusted to $0.44. The dividend was paid on 18 Jul 2025.
Earnings released on 29 Apr 2025
EPS came in at $1.20 surpassing the estimated $0.59 by +103.39%, while revenue for the quarter reached $23.98B .
Earnings released on 13 Mar 2025
EPS came in at -$0.21 falling short of the estimated $0.31 by -169.26%, while revenue for the quarter reached $16.95B .
Earnings released on 25 Oct 2024
EPS came in at $0.38 falling short of the estimated $0.45 by -15.56%, while revenue for the quarter reached $19.94B , beating expectations by +7.15%.
Dividend declared on 15 Oct 2024
A dividend of $0.44 per share was announced, adjusted to $0.44. The dividend was paid on 15 Nov 2024.
Earnings released on 31 Aug 2024
EPS came in at $0.36 falling short of the estimated $0.51 by -29.41%, while revenue for the quarter reached $19.43B .
Dividend declared on 13 Jun 2024
A dividend of $0.82 per share was announced, adjusted to $0.82. The dividend was paid on 18 Jul 2024.
Earnings released on 26 Apr 2024
EPS came in at $1.20 surpassing the estimated $0.70 by +71.43%, while revenue for the quarter reached $24.83B .
Earnings released on 16 Mar 2024
EPS came in at $0.16 falling short of the estimated $0.34 by -52.94%, while revenue for the quarter reached $19.18B .
Earnings released on 30 Oct 2023
EPS came in at $0.60 surpassing the estimated $0.55 by +9.09%, while revenue for the quarter reached $19.54B .
Earnings released on 19 Aug 2023
EPS came in at $0.56 surpassing the estimated $0.53 by +5.66%, while revenue for the quarter reached $19.84B .
Dividend declared on 14 Jun 2023
A dividend of $0.81 per share was announced, adjusted to $0.81. The dividend was paid on 17 Jul 2023.
Earnings released on 31 Mar 2023
EPS came in at $1.34 surpassing the estimated $1.03 by +30.10%, while revenue for the quarter reached $24.69B .
Earnings released on 18 Mar 2023
EPS came in at $0.30 falling short of the estimated $0.37 by -18.92%, while revenue for the quarter reached $18.20B , beating expectations by +20.18%.
Earnings released on 25 Oct 2022
EPS came in at $0.54 surpassing the estimated $0.41 by +31.71%, while revenue for the quarter reached $19.32B , missing expectations by -17.39%.
Earnings released on 20 Aug 2022
EPS came in at $0.48 surpassing the estimated $0.37 by +29.73%, while revenue for the quarter reached $19.53B , missing expectations by -7.19%.
Dividend declared on 10 Jun 2022
A dividend of $0.81 per share was announced, adjusted to $0.81. The dividend was paid on 14 Jul 2022.
Earnings released on 26 Apr 2022
EPS came in at $1.11 surpassing the estimated $0.65 by +70.77%, while revenue for the quarter reached $25.31B .
Earnings released on 19 Mar 2022
EPS came in at $0.25 surpassing the estimated $0.24 by +4.17%, while revenue for the quarter reached $18.95B , beating expectations by +80.13%.
Earnings released on 26 Oct 2021
EPS came in at $0.50 surpassing the estimated $0.38 by +31.58%, while revenue for the quarter reached $21.00B .
Earnings released on 19 Aug 2021
EPS came in at $0.54 surpassing the estimated $0.39 by +38.46%, while revenue for the quarter reached $19.31B .
Dividend declared on 21 Jun 2021
A dividend of $0.65 per share was announced, adjusted to $0.65. The dividend was paid on 27 Jul 2021.
Earnings released on 27 Apr 2021
EPS came in at $1.00 surpassing the estimated $0.56 by +78.57%, while revenue for the quarter reached $23.74B .
Earnings released on 19 Mar 2021
EPS came in at $0.16 falling short of the estimated $0.27 by -40.74%, while revenue for the quarter reached $17.56B .
Earnings released on 28 Oct 2020
EPS came in at $0.55 surpassing the estimated $0.51 by +7.84%, while revenue for the quarter reached $18.72B .
0874.HK Stock Performance
Access detailed 0874.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.